Document Detail


Edaravone prevents bowel infarction after acute superior mesenteric artery thromboembolism using autologous fibrin clots in a rabbit model.
MedLine Citation:
PMID:  19221189     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to evaluate the effects of intra-arterial administration of edaravone after superior mesenteric artery (SMA) thromboembolism in a rabbit model. 24 Japanese white rabbits were randomly allocated to a urokinase group (group U) and a urokinase with edaravone group (group E). A further three rabbits, which were administered an autologous blood clot alone, served as a control group (group C). A 4-Fr sheath was inserted into an SMA. An autologous blood clot was administered to an SMA (group C). After 45 min, urokinase (6000 IU) and heparin (250 IU) were administered through the catheter, either alone (group U) or in conjuction with edaravone (0.5 mg kg(-1)) (group E). In eight rabbits from each of groups U and E, 6 h after reperfusion, the small intestine was harvested and divided into five equal parts. The degree of intestinal tissue injury in each part was rated on a scale of 0-8. After 1 week, survival times and blood biochemistry data were compared among rabbits in group U (four rabbits), group E (four rabbits) and group C (three rabbits), and significant differences (p<0.05) were recorded. Intestinal mucosal damage was significantly greater in group U (5.8 +/- 1.5) than in group E (2.9 +/- 0.7). Survival time tended to be longer in group E (p>0.4, not significant compared with group U). Liver and kidney function showed signs of deterioration over time whether or not edaravone was administered, but administration of edaravone reduced intestinal mucosal damage. An increase in survival rate requires improvements in evaluation methods to enable identification of ischaemic areas.
Authors:
A Sonoda; N Nitta; A Seko; S Ohta; S Takemura; Y Miyagawa; M Takahashi; K Murata
Related Documents :
11961619 - Enteroscopic treatment of early postoperative small bowel obstruction.
6678139 - Whole bowel irrigation--an alternative to traditional bowel washout.
21845999 - Initial stability of tibial components in primary knee arthroplasty. a cadaver study co...
2757509 - Successful surgical treatment of idiopathic colonic dysmotility. the role of preoperati...
20197759 - Ischemic colitis and complications of constipation associated with the use of alosetron...
8500509 - Preservation of small bowel grafts--a comparison with two standard solutions.
18352799 - Early beaten-copper pattern: its long-term effect on intelligence quotients in 95 child...
1838449 - A comparison of single-level fusions with and without hardware.
23347369 - Transepithelial corneal cross-linking in pediatric patients: early results.
Publication Detail:
Type:  Journal Article     Date:  2009-02-16
Journal Detail:
Title:  The British journal of radiology     Volume:  82     ISSN:  1748-880X     ISO Abbreviation:  Br J Radiol     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-09-04     Completed Date:  2009-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0373125     Medline TA:  Br J Radiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  711-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Radiology, Shiga University of Medical Science, Setatsukinowa-cho, Otsu, Shiga 520-2192, Japan. akinagasonoda@yahoo.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticoagulants / therapeutic use
Antipyrine / analogs & derivatives*,  therapeutic use
Case-Control Studies
Disease Models, Animal
Fibrin
Free Radical Scavengers / therapeutic use*
Heparin / therapeutic use
Intestine, Small / drug effects*,  physiopathology
Mesenteric Artery, Superior
Mesenteric Vascular Occlusion / drug therapy
Rabbits
Random Allocation
Reperfusion Injury / prevention & control*
Thromboembolism / drug therapy
Urokinase-Type Plasminogen Activator / administration & dosage
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Free Radical Scavengers; 60-80-0/Antipyrine; 89-25-8/phenylmethylpyrazolone; 9001-31-4/Fibrin; 9005-49-6/Heparin; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does sialography require antibiotic prophylaxis?
Next Document:  Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Ini...